Biofrontera AG (BFFTF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biofrontera AG (BFFTF) trades at $0.33 with AI Score 46/100 (Grade C). Biofrontera AG is a German biopharmaceutical company specializing in dermatological therapies, primarily known for Ameluz and the BF-RhodoLED lamp used in treating actinic keratoses and squamous cell carcinoma. Market cap: $19.35M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for BFFTF: BFFTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BFFTF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BFFTF: the 1 perspectives are evenly split.
How is this calculated? →Biofrontera AG (BFFTF) Healthcare & Pipeline Overview
Biofrontera AG is a German biopharmaceutical firm focused on developing and commercializing dermatological therapies for skin conditions, including actinic keratoses and squamous cell carcinoma, across North America, Europe, and Israel. Its core offerings, Ameluz and BF-RhodoLED, position it within the specialized dermatology market, complemented by pipeline developments in broader anti-infective agents.
What Is the Investment Thesis for BFFTF?
Biofrontera AG presents an investment profile centered on its established dermatological product portfolio, particularly Ameluz and the BF-RhodoLED lamp, which address the persistent need for effective treatments for actinic keratoses and squamous cell carcinoma. The company's high gross margin of 82.8% indicates strong product economics, suggesting significant profitability potential if sales scale and operational efficiencies improve. Key growth catalysts include the ongoing development and potential market introduction of RhodoLED XL for extensive lesions, which could significantly expand the addressable patient population for its PDT platform, and Xepi, targeting antibiotic-resistant bacteria, offering diversification into a critical healthcare segment. The existing partnership with Maruho Co., Ltd. also provides a strategic avenue for market expansion and product development. Despite a current negative profit margin of -25.7% and a relatively small market capitalization of $19.35M, the company's focused R&D and commercialization efforts in dermatology, coupled with a low Beta of 0.59, suggest a potentially stable yet growth-oriented trajectory, contingent on successful pipeline progression and market adoption.
Based on FMP financials and quantitative analysis
BFFTF Key Highlights
- Biofrontera AG maintains a robust gross margin of 82.8%, indicating strong pricing power and cost efficiency for its core dermatological products.
- The company reported a profit margin of -25.7%, reflecting ongoing investments in research and development, commercialization efforts, and operational overhead.
- With a market capitalization of $19.35M, Biofrontera AG operates as a small-cap biopharmaceutical company, offering potential for significant growth but also higher inherent volatility.
- The company's Beta of 0.59 suggests lower volatility compared to the broader market, potentially appealing to investors seeking less market-correlated exposure within the healthcare sector.
- Biofrontera AG employs 97 individuals, indicating a focused operational scale for its specialized dermatological and anti-infective development programs.
Who Are BFFTF's Competitors?
BFFTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BFFTF's Key Strengths?
- Established flagship product Ameluz with high gross margin (82.8%) for actinic keratoses and squamous cell carcinoma.
- Proprietary BF-RhodoLED lamp system, providing a comprehensive photodynamic therapy solution.
- Diversified product pipeline including RhodoLED XL for extensive lesions and Xepi for antibiotic-resistant bacteria.
- International market presence across the United States, Europe, and Israel.
- Strategic partnership with Maruho Co., Ltd. for potential market expansion and development.
What Are BFFTF's Weaknesses?
- Negative profit margin of -25.7%, indicating unprofitability at current scale.
- Small market capitalization ($0.02B), suggesting limited financial resources compared to larger competitors.
- Listing on the OTC Other tier, implying lower liquidity and less stringent reporting requirements.
- Reliance on a limited number of core products for a significant portion of current revenue.
- Unknown status of specific clinical trials and regulatory timelines for pipeline assets.
What Could Drive BFFTF Stock Higher?
- Potential regulatory approvals for RhodoLED XL for extensive interspersed lesions, which could significantly expand the addressable market for Biofrontera's PDT platform.
- Advancement of Xepi through clinical trials and towards regulatory submission, opening a new therapeutic area in antibiotic-resistant infections.
- Expansion of Ameluz market penetration and sales growth in existing territories (US, Europe, Israel) through enhanced commercial strategies.
- Further development and strengthening of the collaborative partnership with Maruho Co., Ltd., potentially leading to new product co-development or market access initiatives.
- Introduction of new dermatological products or indications, either from internal R&D or strategic licensing, diversifying the company's revenue streams.
What Are the Key Risks for BFFTF?
- Financial-distress signal — its Altman Z-Score of -7.40 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- The company's negative profit margin of -25.7% indicates sustained unprofitability, posing a risk to long-term financial sustainability without significant revenue growth or cost control.
- High dependence on the successful commercialization and market acceptance of Ameluz and its pipeline products, particularly RhodoLED XL and Xepi, for future revenue growth.
- Intense competition within the specialized and generic drug manufacturing industry, particularly in dermatology, from larger pharmaceutical companies with greater resources.
- Regulatory risks and potential delays in obtaining approvals for new indications or pipeline products, which could impact market entry timelines and investment returns.
- Risks associated with trading on the OTC Other tier, including lower liquidity, higher price volatility, and limited public disclosure, which can affect investor confidence and capital raising capabilities.
What Are the Growth Opportunities for BFFTF?
- **Expansion of Ameluz Indications and Geographic Reach:** Biofrontera AG's flagship product, Ameluz, currently treats mild to moderate actinic keratoses and squamous cell carcinoma. A significant growth opportunity lies in expanding its approved indications, such as the ongoing development of RhodoLED XL for extensive interspersed lesions, which could unlock a larger patient population. Furthermore, deepening market penetration within its existing territories of the United States, Europe, and Israel, or exploring new geographic markets through strategic partnerships, could drive substantial revenue growth. The global market for actinic keratosis treatments is projected to grow, providing a favorable environment for Ameluz's continued expansion.
- **Development and Commercialization of Xepi:** The development of Xepi, an agent targeting infections from antibiotic-resistant bacteria, represents a strategic diversification opportunity for Biofrontera. The global market for anti-infectives, particularly those addressing drug-resistant pathogens, is substantial and growing due to increasing resistance rates. Successful clinical development, regulatory approval, and subsequent commercialization of Xepi could open a new, high-value revenue stream for the company, leveraging its existing pharmaceutical development expertise and potentially expanding its commercial footprint beyond dermatology into broader infectious disease markets. This pipeline asset could significantly enhance the company's long-term growth trajectory.
- **Leveraging the Maruho Co., Ltd. Partnership:** Biofrontera AG maintains a collaborative and partnership agreement with Maruho Co., Ltd. This strategic alliance can serve as a powerful growth driver by facilitating enhanced market access, particularly in Asian markets, or by providing additional resources for research and development. Expanding the scope of this partnership, whether through co-development of new products, joint commercialization efforts, or licensing agreements for existing products in new territories, could accelerate Biofrontera's global reach and product pipeline. Such collaborations are crucial for smaller biopharmaceutical companies to compete effectively on a global scale.
- **Introduction of New Dermatological Therapies:** Beyond its current pipeline, Biofrontera has the opportunity to develop and introduce entirely new dermatological therapies, either through internal R&D or strategic acquisitions/licensing. The dermatology market is dynamic, with continuous innovation in areas like biologics, gene therapies, and advanced topical formulations. By identifying unmet needs in areas such as chronic inflammatory skin diseases, rare dermatological conditions, or aesthetic dermatology, Biofrontera could expand its product portfolio and address new market segments. This proactive approach to pipeline expansion is essential for sustained long-term growth in the biopharmaceutical sector.
- **Optimizing Commercialization and Market Penetration:** For its existing products like Ameluz, Biofrontera can drive growth by optimizing its commercialization strategies. This includes enhancing sales force effectiveness, expanding physician education programs, and improving patient access initiatives across its key markets in the United States, Europe, and Israel. Increasing awareness among dermatologists and patients about the benefits of photodynamic therapy for actinic keratoses and squamous cell carcinoma can lead to higher prescription rates and market share gains. Focused marketing campaigns and strategic pricing could further solidify Ameluz's position and drive incremental revenue growth in established markets.
What Opportunities Does BFFTF Have?
- Expansion of Ameluz indications and geographic market penetration, particularly with RhodoLED XL.
- Successful development and commercialization of Xepi for antibiotic-resistant infections, opening new market segments.
- Leveraging the Maruho Co., Ltd. partnership for R&D collaboration or market access in Asia.
- Addressing unmet needs in other dermatological conditions through new product development or acquisitions.
- Potential for increased adoption of photodynamic therapy as a preferred treatment modality for skin cancers.
What Threats Does BFFTF Face?
- Intense competition from larger pharmaceutical companies with broader dermatological portfolios.
- Regulatory hurdles and potential delays in obtaining approvals for pipeline products.
- Market acceptance and reimbursement challenges for new therapies.
- Dependence on the success of clinical trials for pipeline assets like RhodoLED XL and Xepi.
- Risks associated with OTC trading, including price volatility and difficulty in capital raising.
What Are BFFTF's Competitive Advantages?
- Proprietary photodynamic therapy (PDT) system combining Ameluz drug with the BF-RhodoLED lamp, offering a distinct treatment modality.
- Established regulatory approvals and market presence for Ameluz in key regions like the US and Europe, creating barriers to entry for new competitors.
- Specialized focus within dermatological oncology, allowing for deep expertise and targeted product development.
- Ongoing pipeline development with products like RhodoLED XL and Xepi, potentially expanding intellectual property and market exclusivity.
- Strategic partnership with Maruho Co., Ltd., potentially providing access to new markets and R&D capabilities.
What Does BFFTF Do?
Biofrontera AG, founded in 1997 and headquartered in Leverkusen, Germany, operates as a biopharmaceutical enterprise dedicated to the exploration, evolution, and commercialization of dermatological therapies. The company has established a significant presence in the treatment of various skin conditions, with its flagship products, Ameluz and the BF-RhodoLED lamp, forming the cornerstone of its commercial strategy. These photodynamic therapy (PDT) solutions are specifically utilized for addressing mild to moderate actinic keratoses on the face and scalp, managing field cancerization, and providing treatment for life-threatening squamous cell carcinoma. This core focus underscores Biofrontera's commitment to addressing critical unmet needs in dermatological oncology. Beyond its established offerings, Biofrontera AG is actively engaged in pipeline development to expand its therapeutic reach. A notable advancement is RhodoLED XL, an innovative extension of its PDT platform, specifically intended for treating extensive interspersed lesions, which promises to broaden the applicability and market potential of its core technology. The company also offers Belixos, a cosmetic product line formulated for sensitive and irritated skin, diversifying its product portfolio within dermatology. Furthermore, Biofrontera is developing Xepi, an agent targeting infections caused by antibiotic-resistant bacteria, indicating a strategic move into the broader anti-infective market, potentially leveraging its existing commercial infrastructure. The company primarily markets its solutions across key international territories, including the United States, Europe, and Israel, demonstrating a global commercial ambition. To support its market penetration and development efforts, Biofrontera maintains a collaborative and partnership agreement with Maruho Co., Ltd., a strategic alliance that could facilitate further growth and market access.
What Products and Services Does BFFTF Offer?
- Develops and commercializes dermatological therapies for various skin conditions.
- Offers Ameluz, a photodynamic therapy for mild to moderate actinic keratoses on the face and scalp.
- Provides the BF-RhodoLED lamp, used in conjunction with Ameluz for photodynamic therapy.
- Treats field cancerization and life-threatening squamous cell carcinoma with its core products.
- Advances RhodoLED XL, a next-generation therapy for extensive interspersed lesions.
- Markets Belixos, a cosmetic product line for sensitive and irritated skin.
- Develops Xepi, an agent targeting infections from antibiotic-resistant bacteria.
- Operates across the United States, Europe, and Israel, with a global commercial focus.
How Does BFFTF Make Money?
- Generates revenue through the sale of its prescription dermatological drug, Ameluz, and its associated medical device, the BF-RhodoLED lamp.
- Derives income from the commercialization of its cosmetic product line, Belixos, targeting sensitive skin.
- Invests in research and development for pipeline products like RhodoLED XL and Xepi, aiming for future commercialization and revenue streams.
- Utilizes a collaborative and partnership agreement with Maruho Co., Ltd. to potentially expand market reach or co-develop products.
- Focuses on a direct sales model in key markets (US, Europe, Israel) for its specialized dermatological products.
What Industry Does BFFTF Operate In?
Biofrontera AG operates within the highly specialized and competitive Drug Manufacturers - Specialty & Generic industry, a segment of the broader Healthcare sector. This industry is characterized by significant R&D expenditures, stringent regulatory pathways, and a constant need for innovation to address evolving medical needs. The dermatology market, Biofrontera's primary focus, is experiencing steady growth driven by an aging population, increased awareness of skin conditions, and advancements in treatment modalities. Biofrontera positions itself by offering targeted photodynamic therapies (PDT) for skin cancers like actinic keratoses and squamous cell carcinoma, areas with established patient populations. While the market features large pharmaceutical players with extensive portfolios, Biofrontera's niche focus with Ameluz and its associated lamp system provides a differentiated offering. The competitive landscape demands continuous product innovation and effective commercialization strategies to maintain and expand market share against both established and emerging therapies.
Who Are BFFTF's Key Customers?
- Dermatologists and other medical professionals prescribing treatments for actinic keratoses and squamous cell carcinoma.
- Patients suffering from mild to moderate actinic keratoses, field cancerization, and squamous cell carcinoma.
- Individuals with sensitive or irritated skin seeking specialized cosmetic care.
- Hospitals and clinics utilizing photodynamic therapy equipment and consumables.
- Healthcare systems and payers covering dermatological treatments in the US, Europe, and Israel.
Company Profile
Biofrontera AG operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Leverkusen, DE. The company is led by CEO Pilar de la Huerta Martinez. BFFTF has traded publicly since 2018.
Biofrontera AG Financial Trajectory
Biofrontera AG (BFFTF) reported $9.0M in revenue for Q3 2024, reflecting 15.0% growth compared to the prior quarter. The company recorded a net loss of $5.7M, with diluted EPS of $-0.98. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
How Biofrontera AG Is Valued
Biofrontera AG carries a market capitalization of $19.35M, placing it in the micro-cap category. Relative to its peer group, BFFTF's quantitative score of 46/100 is below the peer average of 66/100.
Key Financial Metrics
Return on assets is -44.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -84.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.20 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -109.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Biofrontera AG's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.40 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Biofrontera AG revenue of about $76.7M for fiscal 2026, with EPS near $2.36.
BFFTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business see potential upside.
- Community sentiment has shifted positively, with discussions highlighting recent product approvals and their potential market impact.
- Analysts are increasingly optimistic about Biofrontera's growth trajectory, especially in the dermatology sector, which has seen rising demand.
- The company has strengthened its partnerships, which could enhance distribution and brand visibility in key markets.
Bear Case
- Concerns over regulatory hurdles persist, with recent scrutiny on product claims that could delay market entry.
- Social sentiment includes skepticism regarding the sustainability of recent sales growth, with some questioning long-term demand.
- Market perception remains cautious due to competitive pressures from larger pharmaceutical companies entering the same space.
- Insider selling activity has raised red flags, suggesting that some insiders may lack confidence in the short-term performance of the stock.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $9M | -$6M | -$0.98 |
| Q2 2024 | $8M | -$257,000 | -$0.05 |
| Q1 2024 | $8M | -$10M | -$2.88 |
Based on FMP financials and quantitative analysis
BFFTF Latest News
No recent news available for BFFTF.
BFFTF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BFFTF.
Price Targets
Wall Street price target analysis for BFFTF.
BFFTF MoonshotScore
What does this score mean?
The MoonshotScore rates BFFTF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Pilar de la Huerta Martinez
Chief Executive Officer
Pilar de la Huerta Martinez serves as the Chief Executive Officer of Biofrontera AG, where she is responsible for managing the company's 97 employees and overseeing its strategic direction and operational execution. Specific details regarding her educational background, prior career history, and previous leadership roles are not provided in the available source data, thus remaining unknown.
Track Record: Under Pilar de la Huerta Martinez's leadership, Biofrontera AG has continued its focus on the development and commercialization of dermatological therapies, including its flagship product Ameluz. Specific key achievements, strategic decisions, or company milestones directly attributable to her leadership tenure are not detailed in the provided information, thus remaining unknown.
BFFTF OTC Market Information
Biofrontera AG trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group. This tier is typically for companies that are not required to or choose not to provide information to the public markets, or for companies that may be in financial distress. Unlike major exchanges such as the NYSE or NASDAQ, which have strict listing requirements regarding financial health, corporate governance, and disclosure, the OTC Other tier has minimal to no public disclosure requirements. This classification often results in less transparency and higher risk for investors compared to stocks trading on higher OTC tiers (like OTCQX or OTCQB) or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status and OTC Other tier mean investors may have access to less comprehensive and timely financial and operational information, hindering informed decision-making.
- Lower Liquidity and Price Volatility: Trading on the OTC Other tier typically results in lower trading volumes, wider bid-ask spreads, and greater price fluctuations, making it difficult to buy or sell shares efficiently.
- Increased Fraud Risk: The less stringent regulatory oversight on the OTC Other tier can expose investors to a higher risk of fraud or manipulation compared to regulated exchanges.
- Difficulty in Capital Raising: The limited transparency and liquidity can make it challenging for the company to raise capital through equity offerings, potentially impacting its ability to fund operations and growth.
- Limited Analyst Coverage: Stocks on the OTC Other tier often receive little to no coverage from institutional analysts, reducing the availability of independent research and valuation insights.
- Verify the company's current financial statements and annual reports, if any are available, directly from the company or regulatory filings in Germany.
- Research the company's product pipeline and regulatory approval status for Ameluz, RhodoLED XL, and Xepi.
- Investigate the management team's background and track record beyond what is publicly stated.
- Assess the competitive landscape in the dermatological and anti-infective markets to understand market positioning.
- Examine any news or press releases from the company regarding its operations, partnerships, and financial performance.
- Understand the specific risks associated with the OTC Other tier, including liquidity and disclosure limitations.
- Evaluate the strength and terms of the partnership agreement with Maruho Co., Ltd.
- Headquartered in Leverkusen, Germany, suggesting a base in a developed economy with established corporate governance standards.
- Established flagship product, Ameluz, with commercialization across the US, Europe, and Israel, indicating operational legitimacy.
- Maintains a collaborative and partnership agreement with Maruho Co., Ltd., a recognized entity, lending credibility to its business operations.
- Focus on biopharmaceutical development and commercialization, a sector typically requiring significant scientific rigor and regulatory compliance.
- Employs 97 individuals, indicating a functional organizational structure and ongoing operations.
Common Questions About BFFTF (Healthcare)
What does Biofrontera AG do?
Biofrontera AG is a biopharmaceutical company headquartered in Germany, specializing in the development and commercialization of dermatological therapies. Its core business revolves around Ameluz, a photodynamic therapy drug, used in conjunction with the BF-RhodoLED lamp, for treating mild to moderate actinic keratoses on the face and scalp, field cancerization, and squamous cell carcinoma. Beyond these flagship products, Biofrontera is advancing RhodoLED XL for extensive interspersed lesions and developing Xepi, an agent targeting antibiotic-resistant bacterial infections. The company also offers the Belixos cosmetic line for sensitive skin. Biofrontera markets its solutions across the United States, Europe, and Israel, focusing on addressing significant dermatological needs.
What are the main risks for BFFTF?
Investing in Biofrontera AG involves several notable risks. Financially, the company currently operates with a negative profit margin of -25.7%, indicating it is not yet profitable, which raises concerns about its long-term financial viability without substantial revenue growth or improved cost management. Operationally, there is a significant dependence on the successful development, regulatory approval, and market adoption of its pipeline products, such as RhodoLED XL and Xepi. The company also faces intense competition from larger, more established pharmaceutical companies in the dermatology and anti-infective markets. Furthermore, its listing on the OTC Other tier poses risks related to lower liquidity, higher price volatility, and less stringent disclosure requirements, making it potentially more challenging for investors to trade shares or access comprehensive company information.
What is Biofrontera AG's drug pipeline status?
Biofrontera AG is actively advancing its drug pipeline with a focus on expanding its dermatological offerings and venturing into anti-infectives. A key pipeline asset is RhodoLED XL, which is under development as an extension of its established photodynamic therapy platform. This product is specifically intended for the treatment of extensive interspersed lesions, aiming to broaden the applicability of its core technology beyond current indications for Ameluz. Additionally, the company is developing Xepi, an agent designed to target infections caused by antibiotic-resistant bacteria. The current status of Xepi indicates Biofrontera's strategic move into addressing a critical global health challenge, potentially diversifying its therapeutic areas beyond dermatology. The progress of these pipeline candidates through clinical trials and regulatory pathways will be crucial for the company's future growth.
What are the key growth opportunities for BFFTF in healthcare?
Biofrontera AG has several key growth opportunities within the healthcare sector. Firstly, expanding the indications and geographic reach of its flagship product, Ameluz, particularly with the development of RhodoLED XL for extensive lesions, could significantly increase its addressable market in dermatological oncology. Secondly, the successful development and commercialization of Xepi, targeting antibiotic-resistant bacteria, represents a substantial opportunity to enter the large and growing anti-infective market, diversifying its revenue streams. Thirdly, leveraging its strategic partnership with Maruho Co., Ltd. could unlock new market access, particularly in Asia, or facilitate co-development of new therapies. Lastly, continued innovation through internal R&D or strategic acquisitions to introduce new dermatological therapies for unmet needs could further solidify its market position and drive long-term growth.
What are the key factors to evaluate for BFFTF?
Biofrontera AG (BFFTF) holds an AI score of 46/100 (low). Not financial advice.
How frequently does BFFTF data refresh on this page?
BFFTF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BFFTF's recent stock price performance?
Biofrontera AG (BFFTF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established flagship product Ameluz with high gross margin (82.8%) for actinic keratoses and squamous cell carcinoma. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BFFTF overvalued or undervalued right now?
Valuing Biofrontera AG (BFFTF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- CEO background and track record details are limited in the provided source data, leading to 'Unknown' entries.
- Specific market sizes and growth rates for individual products are not provided, so general industry trends are cited.
- Competitor information (FMP PEER TICKERS) was not provided, resulting in an empty competitors array.
- Specific details on clinical trial phases and timelines for pipeline products (RhodoLED XL, Xepi) are not available, so general development status is described.